Kalorama Information

Traditional in vitro diagnostic tests can be interpreted by a physician or lab technologist, but for new complex tests that use DNA sequencing, proteomics or mass spectroscopy, computers are coming to the rescue.

The recent NJ court damages award against TEVA Pharmaceuticals and Sun Pharmaceutical Industries Ltd and in favor of Pfizer is a sign of increasing protection for the pharmaceutical industry.

The global cardiac diagnostics market totaled approximately $13.2 billion in 2012, increasing at a rate of 3.1% from $12.4 billion in 2010. Growth will continue at a faster pace, growing at a rate of 5% for the next few years.

The recent NJ court decision against TEVA Pharmaceuticals and Sun Pharmaceutical Industries Ltd and in favor of Pfizer is a sign of increasing protection for the pharmaceutical industry, according to Kalorama Information.

The world orphan drug market reached $61 billion in 2012. The increasing incidence of diseases affecting the aged will drive the market to increase at a rate of 11.5% throughout the forecast period, reaching a value of $105.2 billion by 2017.

Driven by the use of molecular tests and inelastic pricing for them, the blood testing market is expected to grow in double-digits according to Kalorama Information.

The balanced Supreme Court decision on the Myriad Genetics patent dispute is likely the fix that the molecular in vitro diagnostics industry needed, according to Kalorama Information.

The telemedicine patient monitoring market grew from 4.2 billion in 2007 to over 10 billion dollars in 2012. Though the market is small, it is fast growing with a large amount of competitors and increasing awareness of effectiveness.

The world market for pain management drugs and devices reached $34.9 billion in 2012. The market is growing as a result of the aging population, but also increased awareness of pain and the need for treatment, among other factors.

Kalorama Information believes that new challenges posed by increased nosocomial infections and catheter re-use rates have led to the development of drug coated catheters and the reduction of catheter re-use, which should help the growth of the market